Auriga Upgrades Protalix BioTherapeutics (PLX) to Buy
Get Alerts PLX Hot Sheet
Price: $2.44 --0%
Rating Summary:
3 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 1
Rating Summary:
3 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 1
Join SI Premium – FREE
Auriga upgraded Protalix BioTherapeutics (NYSE: PLX) from Hold to Buy, price target raised from $8 to $9.
For an analyst ratings summary and ratings history on Protalix BioTherapeutics click here. For more ratings news on Protalix BioTherapeutics click here.
Shares of Protalix BioTherapeutics closed at $6.73 yesterday.
For an analyst ratings summary and ratings history on Protalix BioTherapeutics click here. For more ratings news on Protalix BioTherapeutics click here.
Shares of Protalix BioTherapeutics closed at $6.73 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026
- Parade Technologies Ltd. (4966:TT) PT Raised to NT$660 at Nomura/Instinet
- BeiGene, Ltd. (6160:HK) (BGNE) PT Raised to HK$288.70 at Nomura/Instinet
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesRelated Entities
AurigaSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share